Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today ...
The combination of Illumina's Single Cell Prep, NovaSeq X Plus platform, 25B flow cell and DRAGEN analysis software creates a seamless end-to-end workflow enabling the high-throughput processing of ...
Illumina, Inc. ILMN recently entered into a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the ...
Industry Prospects Favor Illumina Per a Grand View Research report, the global single-cell analysis market size was valued at $4.34 billion in 2023 and is projected to witness a CAGR of 18.7% from ...
The copy number variant (CNV) recall was based on Illumina's DRAGEN pipeline. All variants in the GnomAD database with minor allele frequency of <1% and disease-causing variants reported in the Human ...
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...
Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers explore cellular behavior mapped across complex tissues. The announcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results